Charlottesville, VA, United States of America

Adenosine Therapeutics, LLC


USPTO Granted Patents = 5

% Expired Patents = 80.0



Forward Citations = 18

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Jayson Michael Rieger (3 out of 39 patents)

silverMedal Robert Douglas Thompson (3 out of 59 patents)

bronzeMedal Guoquan Wang (2 out of 18 patents)

4.  James F Castner (1 out of 6 patents)

5.  Dianne D Zdankiewicz (1 out of 5 patents)

6.  Anthony Beauglehole (1 out of 10 patents)

7.  Ajit B Thakur (1 out of 6 patents)

8.  Hsun-Wen Hsu (1 out of 1 patent)

9.  James E Anderson (1 out of 1 patent)

10.  Onno Kranenburg (1 out of 1 patent)

11.  Jarmila Van Der Bilt (1 out of 1 patent)

12.  Inne Borel Rinkes (1 out of 1 patent)

13.  Joel M Linden (35 patents)

14.  Gail W Sullivan (22 patents)

15.  Lauren J Murphree (9 patents)


5 patents:

Company Overview
Adenosine Therapeutics, LLC is a biotechnology company focused on the development of novel therapies targeting the adenosine receptor pathway. Our mission is to harness the therapeutic potential of adenosine to address unmet medical needs in various disease areas, including oncology, cardiovascular and neurological disorders.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

5 Patents

#38 in Charlottesville, VA

#922 in Virginia

#51,570 in US

Charlottesville, VA (US)
Charlottesville, VA, United States of America
Forward Citations = 18

12 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Adenosine Therapeutics, LLC. Retrieved from https://idiyas.com/company/adenosine-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…